257: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic - Part 1

About this episode

Milan Tomic discusses the importance of integrating regulatory affairs into drug design based on his 30 years of experience in biotech and GMP manufacturing.

The gap between a “drug” and a true “product” is where many therapies fail. Milan Tomic, biotech veteran, GMP manufacturing expert, and founder of Albrem, has spent 30 years turning promising science into scalable, executable products that can actually reach patients. His experience spans everything from antibody development to building large-scale GMP facilities. Today, he helps biotech teams align scientific innovation with the operational and regulatory realities needed for successful comm...

People in this episode

Host: David Brühlmann

Guest: Milan Tomic

Topics covered

• regulatory affairs
• drug design
• biotech
• GMP manufacturing
• process development

Keywords

• regulatory affairs
• drug design
• biotech
• GMP
• process development
• manufacturing
• therapies

Mentioned in this episode

Organizations: Albrem

More episodes of Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

• 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 2 · June 11, 2026 · 22 min
• 259: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 1 · June 9, 2026 · 25 min
• 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic - Part 2 · June 4, 2026 · 25 min
• 256: Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore with Steffen Kreye - Part 2 · May 28, 2026 · 18 min
• 255: Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore with Steffen Kreye - Part 1 · May 26, 2026 · 26 min
• 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee - Part 2 · May 21, 2026 · 22 min